Page 2,700«..1020..2,6992,7002,7012,702..2,7102,720..»

Pediatric brain tumors traced to brain stem cells

Posted: July 10, 2012 at 3:14 am

ScienceDaily (July 9, 2012) Scientists showed in mice that disabling a gene linked to a common pediatric tumor disorder, neurofibromatosis type 1 (NF1), made stem cells from one part of the brain proliferate rapidly. But the same genetic deficit had no effect on stem cells from another brain region.

The results can be explained by differences in the way stem cells from these regions of the brain respond to cancer-causing genetic changes.

NF1 is among the world's most common genetic disorders, occurring in about one of every 3,000 births. It causes a wide range of symptoms, including brain tumors, learning disabilities and attention deficits.

Brain tumors in children with NF1 typically arise in the optic nerve and do not necessarily require treatment. If optic gliomas keep growing, though, they can threaten the child's vision. By learning more about the many factors that contribute to NF1 tumor formation, scientists hope to develop more effective treatments.

"To improve therapy, we need to develop better ways to identify and group tumors based not just on the way they look under the microscope, but also on innate properties of their stem cell progenitors," says David H. Gutmann, MD, PhD, the Donald O. Schnuck Family Professor of Neurology.

The study appears July 9 in Cancer Cell. Gutmann also is the director of the Washington University Neurofibromatosis Center.

In the new study, researchers compared brain stem cells from two primary sources: the third ventricle, located in the midbrain, and the nearby lateral ventricles. Before birth and for a time afterward, both of these areas in the brain are lined with growing stem cells.

First author Da Yong Lee, PhD, a postdoctoral research associate, showed that the cells lining both ventricles are true stem cells capable of becoming nerve and support cells (glia) in the brain. Next, she conducted a detailed analysis of gene expression in both stem cell types.

"There are night-and-day differences between these two groups of stem cells," Gutmann says. "These results show that stem cells are not the same everywhere in the brain, which has real consequences for human neurologic disease."

The third ventricle is close to the optic chiasm, the point where the optic nerves cross and optic gliomas develop in NF1 patients. Lee and Gutmann postulated that stem cells from this ventricle might be the source of progenitor cells that can become gliomas in children with NF1.

View original post here:
Pediatric brain tumors traced to brain stem cells

Posted in Stem Cells | Comments Off on Pediatric brain tumors traced to brain stem cells

Ovarian Stem Cell Debate

Posted: July 10, 2012 at 3:14 am

Opinion is divided on a new paper showing that adult ovaries do not contain egg-making stem cells, contrary to the findings of two recent studies that themselves appeared to overturn longstanding dogma.

For more than half a century, textbooks have stated that women and other female mammals are born with all the eggs, or oocytes, they will ever have. This supply gradually shrinks with age, and ovaries are incapable of producing more of these reproductive cells.

This dogma has taken a pounding in recent years, however. Starting in 2004, Ji Wu of Shanghai Jiao Tong University in China and Jonathan Tilly of Massachusetts General Hospital isolated stem cells from the ovaries of mice, which could apparently divide to produce fresh oocytes. And earlier this year, Tilly announced that he has found cells with the same qualities, known as oogonial stem cells (OSCs), in the ovaries of middle-aged women.

These discoveries promised to offer new treatments for fertility, allowing women to have babies without worrying about an ageing supply of eggs. But as with all dogma-contradicting discoveries, they remained contentious.

Now, a new study from researchers at the University of Gothenburg is likely to fuel the controversy. Kui Liu and his colleagues used fluorescing proteins to identify the alleged egg-producing stem cells in the ovaries of mice, and found that the cells do not divide into oocytes. They published their results today (July 9) in the Proceedings of the National Academy of Sciences.

The reaction to Lius study is strongly divided. Patricia Hunt, a reproductive biologist from Washington State University, described it as solid and informative. For those of us who have remained skeptical about the existence or role of stem cells in the ovary, this approach is a most welcome addition to the field, she said.

I took a close look at this and the work is fantastic, agreed David Albertini, a physiologist from the University of Kansas. It should put previous discussions into perspective. At least in mice, OSCs do not exist.

But Evelyn Telfer, a cell biologist from the University of Edinburgh, is less impressed, and said that Liu missed the opportunity to obtain robust experimental evidence. Because Liu used completely new methods, it is unclear how the cells he identified compare with those from previous studies. We are left with more questions than answers, said Telfer.

When Liu first saw the papers by Wu and Tilly, he was more excited than sceptical. My first impulse was: I want to repeat this, he said. But he was troubled by the fact that both Wu and Tillys teams fished for their cells using antibodies that recognize DDX4, a protein found in reproductive stem cells. But DDX4 is not a surface protein, Liu said, and is mainly found inside cells. The fishing technique should not have worked.

To avoid this problem, Lius members Hua Zhang and Wenjing Zheng worked with rainbow mice, whose reproductive cells glow green under normal conditions, but change to red, orange, or blue if they switch on the Ddx4 gene. Zhang and Zheng identified several such cells and watched them for 72 hours. They never once divided or produced oocytes. The duo did find some cells that looked like oocytes, but these did not express Ddx4.

More:
Ovarian Stem Cell Debate

Posted in Stem Cells | Comments Off on Ovarian Stem Cell Debate

Egg production after birth questioned

Posted: July 10, 2012 at 3:14 am

Study finds no evidence of stem cells in mouse ovaries

Web edition : 3:53 pm

Women may indeed be limited to the number of eggs their ovaries contain at birth, a new study finds, directly contradicting recent research that suggests otherwise.

Scientists have long thought that female mammals, including humans, are born with all the egg cells they will ever have. But a few papers, culminating with a study published earlier this year in Nature Medicine, have suggested that ovaries contain rare stem cells that can replenish egg supplies (SN: 4/7/12, p. 8). These egg-producing stem cells could lead to new treatments for fertility problems, ways to delay menopause and advancements in the basic understanding of human egg cells.

Not so fast, says Kui Liu, a molecular reproductive biologist at the University of Gothenburg in Sweden. Working with mice, Liu and his colleagues used a technique to identify egg cells and their precursors in ovaries. The team found no evidence of the stem cells in ovaries that reproductive biologist Jonathan Tilly of Massachusetts General Hospital and colleagues recently described in Nature Medicine.

To look for egg-making stem cells in mouse ovaries, Liu and his colleagues genetically engineered mice so that every cell glows green with a fluorescent protein, except for eggs, sperm and cells destined to become gametes. Those cells glow yellow, blue or red. The scientists found cells glowing red purported gamete precursors in the ovary, but those cells did not divide the way stem cells would and did not produce new eggs, leading the researchers to conclude that stem cells dont exist in the ovary. The researchers report their work online July 9 in the Proceedings of the National Academy of Sciences.

The new finding in no way disproves the existence of egg-making stem cells in the ovary, says Evelyn Telfer, a reproductive biologist at the University of Edinburgh. For one thing, these cells are absolutely not the same as the ones Tillys got, she says. The cells Liu found are much larger and are probably already nondividing egg cells.

Liu says his point in publishing the paper is not to say that Tilly is wrong, but to urge scientists to take a hard look at the evidence for and against stem cells in the ovary.

The rest is here:
Egg production after birth questioned

Posted in Stem Cells | Comments Off on Egg production after birth questioned

Discovery of epigenetic links in cell-fate decisions of adult stem cells paves way for new osteoporosis treatments

Posted: July 9, 2012 at 7:22 pm

ScienceDaily (July 9, 2012) The ability to control whether certain stem cells ultimately become bone cells holds great promise for regenerative medicine and potential therapies aimed at treating metabolic bone diseases.

Now, UCLA School of Dentistry professor and leading cancer scientist Dr. Cun-Yu Wang and his research team have made a significant breakthrough in that direction. The scientists have discovered two key epigenetic regulating genes that govern the cell-fate determination of human bone marrow stem cells.

Wang's new research is featured on the cover of the July 6 issue of Cell Stem Cell, the affiliated journal of the International Society for Stem Cell Research.

The groundbreaking study grew out of Wang's desire to better understand the epigenetic regulation of stem cell differentiation, in which the structure of genes is modified while the sequence of the DNA is not. He and his team found that KDM4B and KDM6B, two gene-activating enzymes, can promote stem cells' differentiation into bone cells by removing methyl markers from histone proteins. This process occurs through the activation of certain genes favoring a commitment to one lineage and the concurrent deactivation of genes favoring other lineages.

The findings imply that chemical manipulation of these gene-activating enzymes may allow stem cells to differentiate specifically into bone cells, while inhibiting their differentiation into fat cells. The group's research could pave the way toward identifying potential therapeutic targets for stem cell-mediated regenerative medicine, as well as the treatment of bone disorders like osteoporosis, the most common type of metabolic bone disease.

"Through our recent discoveries on the lineage decisions of human bone marrow stem cells, we may be more effective in utilizing these stem cells for regenerative medicine for bone diseases such as osteoporosis, as well as for bone reconstruction," Wang said. "However, while we know certain genes must be turned on in order for the cells to become bone-forming cells, as opposed to fat cells, we have only a few clues as to how those genes are switched on."

The research group, through its study of aging mice, found that the two enzymes KDM4B and KDM6B could specifically activate genes that promote stem cell differentiation toward bone, while blocking the route toward fat.

"Interestingly, in our aged mice, as well as osteoporotic mice, we observed a higher amount of silencing histone methyl groups which were normally removed by the enzymes KDM4B and KDM6B in young and healthier mice," Wang said. "And since these enzymes can be easily modified chemically, they may become potential therapeutic targets in tissue regeneration and treatment for osteoporosis."

"The discovery that Dr. Wang and his team have made has considerable implications for craniofacial bone regeneration and treatment for osteoporosis," said Dr. No-Hee Park, dean of the UCLA School of Dentistry. "As a large portion of our population reaches an age where osteoporosis and gum disease could be major health problems, advancements in aging-related treatment are very valuable."

Professor Wang holds the No-Hee Park Endowed Chair in Dentistry at the UCLA School of Dentistry, where he is also chair of the division of oral biology and medicine and the associate dean for graduate studies.

View post:
Discovery of epigenetic links in cell-fate decisions of adult stem cells paves way for new osteoporosis treatments

Posted in Regenerative Medicine | Comments Off on Discovery of epigenetic links in cell-fate decisions of adult stem cells paves way for new osteoporosis treatments

UCLA researcher discovers epigenetic links in cell-fate decisions of adult stem cells

Posted: July 9, 2012 at 7:22 pm

Public release date: 6-Jul-2012 [ | E-mail | Share ]

Contact: Brianna Deane bdeane@dentistry.ucla.edu 310-206-0835 University of California - Los Angeles

The ability to control whether certain stem cells ultimately become bone cells holds great promise for regenerative medicine and potential therapies aimed at treating metabolic bone diseases.

Now, UCLA School of Dentistry professor and leading cancer scientist Dr. Cun-Yu Wang and his research team have made a significant breakthrough in that direction. The scientists have discovered two key epigenetic regulating genes that govern the cell-fate determination of human bone marrow stem cells.

Wang's new research is featured on the cover of the July 6 issue of Cell Stem Cell, the affiliated journal of the International Society for Stem Cell Research.

The groundbreaking study grew out of Wang's desire to better understand the epigenetic regulation of stem cell differentiation, in which the structure of genes is modified while the sequence of the DNA is not. He and his team found that KDM4B and KDM6B, two gene-activating enzymes, can promote stem cells' differentiation into bone cells by removing methyl markers from histone proteins. This process occurs through the activation of certain genes favoring a commitment to one lineage and the concurrent deactivation of genes favoring other lineages.

The findings imply that chemical manipulation of these gene-activating enzymes may allow stem cells to differentiate specifically into bone cells, while inhibiting their differentiation into fat cells. The group's research could pave the way toward identifying potential therapeutic targets for stem cellmediated regenerative medicine, as well as the treatment of bone disorders like osteoporosis, the most common type of metabolic bone disease.

"Through our recent discoveries on the lineage decisions of human bone marrow stem cells, we may be more effective in utilizing these stem cells for regenerative medicine for bone diseases such as osteoporosis, as well as for bone reconstruction," Wang said. "However, while we know certain genes must be turned on in order for the cells to become bone-forming cells, as opposed to fat cells, we have only a few clues as to how those genes are switched on."

The research group, through its study of aging mice, found that the two enzymes KDM4B and KDM6B could specifically activate genes that promote stem cell differentiation toward bone, while blocking the route toward fat.

"Interestingly, in our aged mice, as well as osteoporotic mice, we observed a higher amount of silencing histone methyl groups which were normally removed by the enzymes KDM4B and KDM6B in young and healthier mice," Wang said. "And since these enzymes can be easily modified chemically, they may become potential therapeutic targets in tissue regeneration and treatment for osteoporosis."

View post:
UCLA researcher discovers epigenetic links in cell-fate decisions of adult stem cells

Posted in Regenerative Medicine | Comments Off on UCLA researcher discovers epigenetic links in cell-fate decisions of adult stem cells

Verastem to Present at the JMP Securities Healthcare Conference 2012

Posted: July 9, 2012 at 4:13 pm

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Verastem, Inc., (VSTM) a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, announced that the Company will present at the JMP Securities Healthcare Conference 2012 on July 13, 2012, in New York City.

The Verastem presentation will be at 9:00am ET on Friday, July 13, 2012, in the Tribeca Room at the Peninsula Hotel in New York, NY.

A webcast of the presentation can be accessed by visiting the investors section of the Companys website at http://www.verastem.com. A replay of the webcast will be archived on the Verastem website for two weeks following the presentation date.

About Verastem, Inc.

Verastem, Inc. (VSTM) is a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. For more information please visit http://www.verastem.com.

Forward-looking statements:

Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Companys views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.

Link:
Verastem to Present at the JMP Securities Healthcare Conference 2012

Posted in Stem Cells | Comments Off on Verastem to Present at the JMP Securities Healthcare Conference 2012

Capricor Announces FDA Approval To Initiate ALLSTAR Trial of Allogeneic Stem Cell Therapy In Patients Following Heart …

Posted: July 9, 2012 at 4:13 pm

LOS ANGELES--(BUSINESS WIRE)--Capricor, Inc., a privately held biotechnology company focused on regenerative medicine, today announced that the U.S. Food and Drug Administration has approved initiation of its Investigational New Drug (IND) application for the ALLSTAR study, which will use allogeneic cardiac-derived stem cells (CDCs) to treat patients following large myocardial infarctions (MI).

IND approval for ALLSTAR is another major milestone for Capricor as we continue to develop cardiac-derived stem cells for the treatment of heart disease

ALLSTAR will study the use of CAP-1002 delivered directly into a coronary artery from thirty days to one year following a heart attack. The trial will have a 14 patient lead in phase and is planned as a 260 patient, twenty center randomized controlled trial. ALLSTAR will study a variety of safety and effectiveness endpoints with the goal of demonstrating sufficiently strong data to permit an eventual Phase III trial as a path to commercialization of CAP-1002.

ALLSTAR is predicated on the positive results of the landmark CADUCEUS trial that showed approximately 50 percent reduction of scar size and 50 percent more viable muscle in the infarction zones of patients studied one year after a heart attack. ALLSTAR will use donor cells whereas CADUCEUS used each patients own CDCs. The shift from autologous to allogeneic cells is supported by extensive pre-clinical evidence of safety and effectiveness and is expected to expand the market opportunity as well as to reduce the costs for treatment.

"IND approval for ALLSTAR is another major milestone for Capricor as we continue to develop cardiac-derived stem cells for the treatment of heart disease," said Linda Marbn, Ph.D., CEO of Capricor. "There are greater than 6 million people in the US living with heart failure, and that number continues to rise as heart disease remains the number one killer. Capricors CDCs represent a novel treatment to repair the heart after muscle loss following large heart attacks through the regeneration of heart muscle and the shrinking of scar tissue. Our ultimate goal will be to demonstrate that muscle regeneration in these patients will result in clinically meaningful improvements to their lives."

"This is terrific news, says Ellen Feigal, M.D., Senior Vice President for Research and Development at Californias stem cell agency, CIRM. This is the first time a Disease Team funded by CIRM has been given an Investigational New Drug (IND) approval from the FDA, a critical step in testing promising therapies in patients. Its a reflection of the progress being made in turning promising therapies into real-world treatments.

Capricor has asked CIRM to assist in the funding of a portion of ALLSTAR. Capricor was founded Baltimore and moved to California almost five years ago in part because of the environment that CIRM has created to foster stem cell research in this state. We are grateful to have received the seed support from CIRM that has funded a portion of our research. Our mission is to develop meaningful treatments for patients suffering from heart disease and to grow Capricor into a major California biotechnology company, said Linda Marbn.

About CAP-1002

CAP-1002, Capricor's lead candidate, is a proprietary allogeneic adult stem cell product for the treatment of myocardial infarction. The product contains multiple progenitor cells and is derived from donor heart tissue. The cells are multiplied in the laboratory using a specialized process, and then introduced directly into a patients heart via infusion in a coronary artery at the time of standard cardiac catherization.

About Capricor, Inc.

See the original post:
Capricor Announces FDA Approval To Initiate ALLSTAR Trial of Allogeneic Stem Cell Therapy In Patients Following Heart ...

Posted in Stem Cells | Comments Off on Capricor Announces FDA Approval To Initiate ALLSTAR Trial of Allogeneic Stem Cell Therapy In Patients Following Heart …

Discovery of epigenetic links in cell-fate decisions of adult stem cells paves way for new osteoporosis treatments

Posted: July 9, 2012 at 4:13 pm

ScienceDaily (July 9, 2012) The ability to control whether certain stem cells ultimately become bone cells holds great promise for regenerative medicine and potential therapies aimed at treating metabolic bone diseases.

Now, UCLA School of Dentistry professor and leading cancer scientist Dr. Cun-Yu Wang and his research team have made a significant breakthrough in that direction. The scientists have discovered two key epigenetic regulating genes that govern the cell-fate determination of human bone marrow stem cells.

Wang's new research is featured on the cover of the July 6 issue of Cell Stem Cell, the affiliated journal of the International Society for Stem Cell Research.

The groundbreaking study grew out of Wang's desire to better understand the epigenetic regulation of stem cell differentiation, in which the structure of genes is modified while the sequence of the DNA is not. He and his team found that KDM4B and KDM6B, two gene-activating enzymes, can promote stem cells' differentiation into bone cells by removing methyl markers from histone proteins. This process occurs through the activation of certain genes favoring a commitment to one lineage and the concurrent deactivation of genes favoring other lineages.

The findings imply that chemical manipulation of these gene-activating enzymes may allow stem cells to differentiate specifically into bone cells, while inhibiting their differentiation into fat cells. The group's research could pave the way toward identifying potential therapeutic targets for stem cell-mediated regenerative medicine, as well as the treatment of bone disorders like osteoporosis, the most common type of metabolic bone disease.

"Through our recent discoveries on the lineage decisions of human bone marrow stem cells, we may be more effective in utilizing these stem cells for regenerative medicine for bone diseases such as osteoporosis, as well as for bone reconstruction," Wang said. "However, while we know certain genes must be turned on in order for the cells to become bone-forming cells, as opposed to fat cells, we have only a few clues as to how those genes are switched on."

The research group, through its study of aging mice, found that the two enzymes KDM4B and KDM6B could specifically activate genes that promote stem cell differentiation toward bone, while blocking the route toward fat.

"Interestingly, in our aged mice, as well as osteoporotic mice, we observed a higher amount of silencing histone methyl groups which were normally removed by the enzymes KDM4B and KDM6B in young and healthier mice," Wang said. "And since these enzymes can be easily modified chemically, they may become potential therapeutic targets in tissue regeneration and treatment for osteoporosis."

"The discovery that Dr. Wang and his team have made has considerable implications for craniofacial bone regeneration and treatment for osteoporosis," said Dr. No-Hee Park, dean of the UCLA School of Dentistry. "As a large portion of our population reaches an age where osteoporosis and gum disease could be major health problems, advancements in aging-related treatment are very valuable."

Professor Wang holds the No-Hee Park Endowed Chair in Dentistry at the UCLA School of Dentistry, where he is also chair of the division of oral biology and medicine and the associate dean for graduate studies.

Read the rest here:
Discovery of epigenetic links in cell-fate decisions of adult stem cells paves way for new osteoporosis treatments

Posted in Regenerative Medicine | Comments Off on Discovery of epigenetic links in cell-fate decisions of adult stem cells paves way for new osteoporosis treatments

UCLA researcher discovers epigenetic links in cell-fate decisions of adult stem cells

Posted: July 9, 2012 at 4:13 pm

Public release date: 6-Jul-2012 [ | E-mail | Share ]

Contact: Brianna Deane bdeane@dentistry.ucla.edu 310-206-0835 University of California - Los Angeles

The ability to control whether certain stem cells ultimately become bone cells holds great promise for regenerative medicine and potential therapies aimed at treating metabolic bone diseases.

Now, UCLA School of Dentistry professor and leading cancer scientist Dr. Cun-Yu Wang and his research team have made a significant breakthrough in that direction. The scientists have discovered two key epigenetic regulating genes that govern the cell-fate determination of human bone marrow stem cells.

Wang's new research is featured on the cover of the July 6 issue of Cell Stem Cell, the affiliated journal of the International Society for Stem Cell Research.

The groundbreaking study grew out of Wang's desire to better understand the epigenetic regulation of stem cell differentiation, in which the structure of genes is modified while the sequence of the DNA is not. He and his team found that KDM4B and KDM6B, two gene-activating enzymes, can promote stem cells' differentiation into bone cells by removing methyl markers from histone proteins. This process occurs through the activation of certain genes favoring a commitment to one lineage and the concurrent deactivation of genes favoring other lineages.

The findings imply that chemical manipulation of these gene-activating enzymes may allow stem cells to differentiate specifically into bone cells, while inhibiting their differentiation into fat cells. The group's research could pave the way toward identifying potential therapeutic targets for stem cellmediated regenerative medicine, as well as the treatment of bone disorders like osteoporosis, the most common type of metabolic bone disease.

"Through our recent discoveries on the lineage decisions of human bone marrow stem cells, we may be more effective in utilizing these stem cells for regenerative medicine for bone diseases such as osteoporosis, as well as for bone reconstruction," Wang said. "However, while we know certain genes must be turned on in order for the cells to become bone-forming cells, as opposed to fat cells, we have only a few clues as to how those genes are switched on."

The research group, through its study of aging mice, found that the two enzymes KDM4B and KDM6B could specifically activate genes that promote stem cell differentiation toward bone, while blocking the route toward fat.

"Interestingly, in our aged mice, as well as osteoporotic mice, we observed a higher amount of silencing histone methyl groups which were normally removed by the enzymes KDM4B and KDM6B in young and healthier mice," Wang said. "And since these enzymes can be easily modified chemically, they may become potential therapeutic targets in tissue regeneration and treatment for osteoporosis."

See the rest here:
UCLA researcher discovers epigenetic links in cell-fate decisions of adult stem cells

Posted in Regenerative Medicine | Comments Off on UCLA researcher discovers epigenetic links in cell-fate decisions of adult stem cells

ACT Secures Approval to Proceed with Increased RPE Dosage for Patients in Clinical Trial for Dry AMD

Posted: July 9, 2012 at 4:13 pm

MARLBOROUGH, Mass.--(BUSINESS WIRE)--

Advanced Cell Technology, Inc. (ACT; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Data and Safety Monitoring Board (DSMB), an independent group of medical experts closely monitoring the companys three ongoing clinical trials, has authorized the company to move forward with enrollment and treatment of additional patients in its clinical trial for dry age-related macular degeneration (dry AMD). ACT will proceed with patient screening and enrollment for the second cohort, who, in keeping with trial protocol, will be injected with 100,000 retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs), as compared with the 50,000-cell dose used in the first cohort.

DSMB authorization to move to the higher dosage of cells in our clinical trial for dry AMD represents a significant milestone for our clinical programs, commented Gary Rabin, chairman and CEO of ACT. Our RPE program is now advancing rapidly, as we are now screening at multiple ophthalmological centers for the fourth surgery in both our dry AMD trial and our U.S. SMD trial, with our E.U. SMD trial, which was initiated much later, not far behind.

The trial is a prospective, open-label study, designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation into patients with dry AMD at 12 months, the studys primary endpoint. The three procedures comprising the first cohort of patients were all conducted at University of California at Los Angeles (UCLA), by Steven Schwartz, M.D., Ahmanson Professor of Ophthalmology at the David Geffen School of Medicine at UCLA and retina division chief at UCLA's Jules Stein Eye Institute. It was announced in May that Mass Eye and Ear is an additional site for the trial.

Mr. Rabin added, Dry AMD represents one of the largest unmet ophthalmological needs in the world, with a potential market of $25 billion in the U.S. and Europe, alone, and this DSMB approval is a big step toward being able to potentially address that massive medical need.

ACT is conducting a total of three clinical trials in the U.S. and Europe using hESC-derived RPE cells to treat forms of macular degeneration. Each trial will enroll a total of 12 patients, with cohorts of three patients each in an ascending dosage format. Treatment of the final patient of the first cohort in the companys dry AMD trial was announced on April 20. On June 29, the second SMD patient enrolled in the Companys E.U. clinical trial was treated at Moorfields Eye Hospital in London, U.K., and on April 24 the company announced DSMB approval to treat the second patient cohort in its U.S. SMD trial.

Further information about patient eligibility for ACTs dry AMD study and the companys concurrent SMD studies in the U.S. and E.U. is available at http://www.clinicaltrials.gov, with the following Identifiers: NCT01344993 (dry AMD), NCT01345006 (U.S. SMD), and NCT01469832 (E.U. SMD).

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.

Forward-Looking Statements

Original post:
ACT Secures Approval to Proceed with Increased RPE Dosage for Patients in Clinical Trial for Dry AMD

Posted in Regenerative Medicine | Comments Off on ACT Secures Approval to Proceed with Increased RPE Dosage for Patients in Clinical Trial for Dry AMD

Page 2,700«..1020..2,6992,7002,7012,702..2,7102,720..»